

8<sup>th</sup> April, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**The National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**Script Code: 500259**

**Script Code: LYKALABS**

Dear Sir/s

**Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the LODR)**

Pursuant to the Regulation 30 and other applicable provisions of the LODR, we are pleased to inform you that Company has been granted a patent for Indian Patent for its proprietary product, "Pregabalin Gel 8%" by Patent Office India.

A copy of the press release issued by the Company in this regard is enclosed herewith.

Kindly take the above information on your record.

Thanking you.

Yours faithfully,  
For **Lyka Labs Limited**

**Shekhar R Singh**  
Company Secretary

Encl.: as above

Date: 8<sup>th</sup> April, 2025

## Lyka Labs Limited Secures Indian Patent for Pregabalin Gel 8% – A Novel Topical Solution for Diabetic Neuropathic Pain

**Lyka Labs Limited** is pleased to announce that it has been granted an **Indian Patent** for its proprietary product, **Pregabalin Gel 8%**, with patent protection valid through **2043**. This significant milestone reinforces Lyka's focus on innovation and its leadership in developing topical drug delivery systems.

**Pregabalin Gel 8%**, a topical formulation designed for the effective management of **diabetic neuropathic pain**, received **regulatory approval from the Central Drugs Standard Control Organization (CDSCO)** in **October 2024** for manufacturing and marketing in India. The product was officially launched in **December 2024** by **Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare** under a **P2P (Product-to-Product) license** from Lyka Labs.

This gel formulation represents a **first-of-its-kind innovation in India**, offering localized delivery of pregabalin directly at the site of pain, potentially minimizing systemic exposure and related side effects commonly associated with oral formulations.

Lyka Labs has conducted **clinical studies** supporting the efficacy, safety, and patient convenience of Pregabalin Gel 8%, making it a promising alternative for millions suffering from chronic diabetic neuropathic conditions.

With this patent, Lyka Labs strengthens its intellectual property portfolio and reaffirms its vision to be at the forefront of innovative pharmaceutical solutions.

### About Lyka Labs Limited

Lyka is a pharmaceutical company with strong capabilities in Sterile Preparations & Topical Preparations. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery Systems in its focus areas of Lyophilized Injectables and Topical Preparations.

For more Information:

Lyka Labs Limited  
**Dr Rajan S Samant**  
Chief Scientific Officer  
[rssamant@lykalabs.com](mailto:rssamant@lykalabs.com)